Targeting Optimal DRUG DELIVERY

In recent years, several innovations have emerged around long-acting formulations and medical device development to improve patient compliance. Consequently, the growing need for controlled drug release coupled with technological advancements in pharmacology is promoting the adoption of novel drug delivery systems (NDDS). It is now crucial for Asia Pacific (APAC) drug formulators to learn and act upon these advances in therapeutic modalities that address long-standing bioavailability, dosage, and ingestion challenges of drug components to remain competitive in the global market. Simultaneously, it's essential to optimise the therapeutic efficacy and safety profiles of a drug by regulating dosage parameters, while DDS plays an important role in administering drugs, vaccines, and therapeutic agents. Optimising these techniques enhance the performance efficacy ratio of medications by economically managing therapeutics assets. Let's examine recent advancements in drug delivery modalities that are greatly encouraging stakeholders' collaboration among innovators, manufacturers, investors, and contract development and manufacturing companies (CDMOs) who are capitalising on competitive advantages.

- Hithashi C Bhaskar

Advancements in the drug delivery systems (DDS) are gradually offering solutions to the rising prevalence of chronic conditions. It is now more crucial than ever before to improve patient compliance while lowering the cost of treatment. As drug manufacturers strive to overcome patient compliance concerns, both small molecules and large molecule active pharmaceutical ingredients (APIS) need to be efficiently managed to achieve the desired therapeutic effect in moderate dosage.

According to experts a significant proportion of APIs or drugs on the whole, exhibit low solubility, low bioavailability, and/or low inconsistent dissolution rate. For biopharmaceutical pipelines to advance, it is essential to address these concerns effectively by identifying, resolving, and reinventing drug delivery channels. Maximising solubility and absorption eliminate the need for reformulation and, hence, promotes the market reach of a drug candidate. Utilising complementary drug delivery technologies can achieve a full range of absorption profiles by modulating pharmacokinetics. As a result, CDMOS are developing a portfolio of bioavailability enhancement technologies and services.

Recent developments in DDS